Harlan Robins Sells 6,160 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Harlan Robins sold 6,160 shares of the company’s stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $18.01, for a total transaction of $110,941.60. Following the completion of the transaction, the insider owned 1,405,898 shares of the company’s stock, valued at $25,320,222.98. This represents a 0.44% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Adaptive Biotechnologies Stock Performance

Shares of ADPT stock opened at $17.54 on Friday. The stock’s 50-day moving average is $14.80 and its two-hundred day moving average is $15.57. Adaptive Biotechnologies Corporation has a 1 year low of $9.96 and a 1 year high of $20.76. The firm has a market cap of $2.81 billion, a price-to-earnings ratio of -53.16 and a beta of 2.15.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.03. The business had revenue of $70.87 million during the quarter, compared to the consensus estimate of $61.03 million. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.The business’s quarterly revenue was up 35.1% on a year-over-year basis. During the same period in the previous year, the business earned ($0.20) EPS. As a group, research analysts predict that Adaptive Biotechnologies Corporation will post -0.47 EPS for the current year.

Institutional Trading of Adaptive Biotechnologies

A number of hedge funds have recently added to or reduced their stakes in ADPT. AQR Capital Management LLC grew its stake in shares of Adaptive Biotechnologies by 45.8% in the 1st quarter. AQR Capital Management LLC now owns 310,272 shares of the company’s stock valued at $2,265,000 after purchasing an additional 97,444 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Adaptive Biotechnologies by 4.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 68,830 shares of the company’s stock worth $511,000 after purchasing an additional 2,914 shares during the last quarter. Caxton Associates LLP purchased a new stake in shares of Adaptive Biotechnologies during the first quarter worth approximately $93,000. New York State Common Retirement Fund lifted its holdings in shares of Adaptive Biotechnologies by 39.2% during the second quarter. New York State Common Retirement Fund now owns 47,258 shares of the company’s stock worth $551,000 after purchasing an additional 13,300 shares during the period. Finally, Arrowstreet Capital Limited Partnership lifted its holdings in shares of Adaptive Biotechnologies by 728.8% during the second quarter. Arrowstreet Capital Limited Partnership now owns 379,120 shares of the company’s stock worth $4,417,000 after purchasing an additional 333,379 shares during the period. 99.17% of the stock is owned by institutional investors and hedge funds.

Adaptive Biotechnologies News Summary

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: BTIG Research reaffirmed its Buy rating on Adaptive Biotechnologies and set a $22 price target, implying upside from recent trading levels.
• Positive Sentiment: The company said part of the convertible-note proceeds will be used for a $25 million stock repurchase and capped-call transactions, which may help offset dilution risk.
• Neutral Sentiment: The notes carry an initial conversion price of about $24.11 per share, which is well above the recent share price and suggests management is trying to limit near-term dilution.
• Negative Sentiment: Adaptive Biotechnologies priced an upsized $300 million convertible debt deal, up from $250 million, which some investors may read as a larger-than-expected financing need.
• Negative Sentiment: Insider selling also weighed on sentiment: Chief Scientific Officer Harlan S. Robins sold 106,160 shares in recent transactions, and the recent insider activity has been entirely sales.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Morgan Stanley decreased their price objective on Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating for the company in a report on Tuesday, May 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Monday, April 20th. Guggenheim reiterated a “buy” rating and issued a $21.00 price target on shares of Adaptive Biotechnologies in a research report on Wednesday, May 6th. Wall Street Zen cut shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Finally, BTIG Research reiterated a “buy” rating and set a $22.00 price target on shares of Adaptive Biotechnologies in a research note on Wednesday. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Adaptive Biotechnologies has a consensus rating of “Moderate Buy” and an average target price of $20.33.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.